Northwestern Memorial joins InVivo Therapeutics neuro-spinal scaffold trial

InVivo Therapeutics (NSDQ:NVIV) said today that Chicago’s Northwestern Memorial Hospital is the 23rd site to join the clinical trial of its neuro-spinal scaffold. “Chicago, as with other major metropolitan areas, sees a disproportionally high number of acute, traumatic spinal cord injuries and unfortunately, with complete spinal cord injuries, trauma teams have limited tools at their disposal to treat this devastating condition. I look forward to being a part of the encouraging Inspire study,” site principal investigator Dr. Nader Dahdaleh said in prepared remarks. “We welcome Dr. Dahdaleh and the team at Northwestern Memorial Hospital to the Inspire study. With this addition, we now have a site in each of the top 6 most populated cities in the U.S.,” added InVivo chairman & CEO Mark Perrin. The Cambridge, Mass.-based company said yesterday that the Inspire trial’s conversion rate for improvement in the American Spinal Injury Assn.’s 50-point lower extremity motor score is 62.5% – more than double the trial’s objective performance criterion of 25% at 6 months. InVivo said that the trial’s 9th spinal cord injury patient, implanted with its neuro-spinal scaffold last month, is already showing signs of improvement. The device is surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. The trial’s 9th patient improved from a complete to incomplete spinal co...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Regenerative Medicine Spinal InVivo Therapeutics Corp. Source Type: news